The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent
Official Title: Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent
Study ID: NCT02602990
Brief Summary: A non-interventional multicentric study for patients with a cerebral AVM for which endovascular treatment is indicated.
Detailed Description: This observational study will collect data about the treatment of ruptured, unruptured, untreated or endovascular previously treated AVM's. Primary endpoint is safety. Safety will be assessed with the number of procedure-related complications occurring during the endovascular treatment until 30 days after the final embolization. Secondary endpoint is efficacy. Efficacy will be assessed by angiography and clinical outcome assessments (mRS). For each patient enrolled, data will be collected at inclusion, at each embolization session and at 6 ± 1 months after the end of the endovascular treatment phase.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UZ Antwerpen, Edegem, , Belgium
Ziekenhuis Oost Limburg (ZOL), Genk, , Belgium
AZ Sint-Lucas, Gent, , Belgium
AZ Groeninge, Kortrijk, , Belgium
UZ Leuven, Leuven, , Belgium
Alfried Krupp Krankenhaus, Essen, , Germany